{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:40:40Z","timestamp":1787928040944,"version":"build-2784847793"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Blau syndrome is a rare autosomal dominant autoinflammatory granulomatous disease caused by a mutation in the <jats:italic>NOD2<\/jats:italic> gene. It is characterized by a clinical trial of granulomatous dermatitis, arthritis, and uveitis. Tofacitinib is a pan Janus kinase (JAK) inhibitor used for treatment of Blau syndrome and idiopathic sarcoidosis. Here, we evaluated its effect on inflammatory pathways associated with Blau syndrome. The effect of tofacitinib on downstream pathways regulated by mutant <jats:italic>NOD2<\/jats:italic> was analyzed using luciferase assays with overexpression of <jats:italic>NOD2<\/jats:italic> mutants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The effect of tofacitinib on the upstream pathway for the induction of <jats:italic>NOD2<\/jats:italic> expression and proinflammatory cytokine production was assessed using monocytic cell lines differentiated from Blau syndrome patient-derived induced pluripotent stem cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tofacitinib did not suppress the increased spontaneous transcriptional activity of NF-\u03baB by mutant <jats:italic>NOD2<\/jats:italic>. In addition, mutant <jats:italic>NOD2<\/jats:italic> was not involved in the transcription of ISRE and GAS, which are activated by type 1 and type 2 interferons (IFN), respectively. On the other hand, IFN\u03b3 induced the expression of <jats:italic>NOD2<\/jats:italic>, which led to the production of inflammatory cytokines by an autoinflammatory mechanism only in cells with mutant <jats:italic>NOD2<\/jats:italic>. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Tofacitinib suppressed the induction of <jats:italic>NOD2<\/jats:italic> by IFN\u03b3, thereby inhibiting the production of pro-inflammatory cytokines. Thus, tofacitinib showed anti-inflammatory effects through suppression of <jats:italic>NOD2<\/jats:italic> expression. The JAK inhibitor tofacitinib is a potential therapeutic agent for Blau syndrome because it suppresses the autoinflammation seen in Blau syndrome by inhibiting the expression of <jats:italic>NOD2<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1211240","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:44:49Z","timestamp":1687340689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Yoko","family":"Ueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Takimoto-Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu K.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotomo","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2972","article-title":"Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with blau syndrome","volume":"105","author":"Kanazawa","year":"2005","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.08.017","article-title":"Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series","volume":"187","author":"Sarens","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu437","article-title":"Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes","volume":"54","author":"Rose","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng720","article-title":"CARD15 mutations in blau syndrome","volume":"29","author":"Miceli-Richard","year":"2001","journal-title":"Nat Genet"},{"key":"B5","article-title":"Blau syndrome mutation of CARD15\/NOD2 in sporadic early onset granulomatous arthritis","volume":"32","author":"Rose","year":"2005","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(85)80394-2","article-title":"Familial granulomatous arthritis, iritis, and rash","volume":"107","author":"Blau","year":"1985","journal-title":"J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008072200","article-title":"Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB","volume":"276","author":"Ogura","year":"2001","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdermsci.2005.04.001","article-title":"The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders","volume":"39","author":"Kambe","year":"2005","journal-title":"J Dermatol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/35079114","article-title":"A frameshift mutation in NOD2 associated with susceptibility to crohn's disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217320","article-title":"Clinical characteristics and treatment of 50 cases of blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation","volume":"79","author":"Matsuda","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24134","article-title":"Role of the NOD2 genotype in the clinical phenotype of blau syndrome and early-onset sarcoidosis","volume":"60","author":"Okafuji","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/ar3462","article-title":"A new category of autoinflammatory disease associated with NOD2 gene mutations","volume":"13","author":"Yao","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/08916934.2018.1442442","article-title":"Alterations in nucleotide-binding oligomerization domain-2 expression, pathway activation, and cytokine production in yao syndrome","volume":"51","author":"McDonald","year":"2018","journal-title":"Autoimmunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.025","article-title":"Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations","volume":"68","author":"Yao","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev207","article-title":"NOD2-associated autoinflammatory disease: a large cohort study","volume":"54","author":"Yao","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaci.2017.04.013","article-title":"Pluripotent stem cell models of blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages","volume":"141","author":"Takada","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/children8020117","article-title":"2 mutation-associated case with blau syndrome triggered by BCG vaccination","volume":"8","author":"Arakawa","year":"2021","journal-title":"Children (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00634-x","article-title":"Tofacitinib effectiveness in blau syndrome: a case series of Chinese paediatric patients","volume":"19","author":"Zhang","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22473","article-title":"Prolonged circulation half-life of interferon gamma activity by gene delivery of interferon gamma-serum albumin fusion protein in mice","volume":"100","author":"Miyakawa","year":"2011","journal-title":"J Pharm Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.030","article-title":"Anti-TNF treatment corrects IFN-gamma-dependent proinflammatory signatures in blau syndrome patient-derived macrophages","volume":"149","author":"Kitagawa","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-Concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.11.016","article-title":"Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy","volume":"7","author":"Singh","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2020.12.021","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil","volume":"9","author":"Alam","year":"2021","journal-title":"JAAD Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1211240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:44:53Z","timestamp":1687340693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1211240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2023.1211240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1211240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"article-number":"1211240"}}